The product identified as Interferon Alfa 2b Effervescent Tablets Pharma Grade API for Tablet / Capsule / Granule / Injection, Oral & Injectable is a recombinant human interferon alpha-2b drug substance supplied for downstream formulation into multiple presentations. The molecule is expressed in Escherichia coli as a non-glycosylated polypeptide of 165 amino acid residues, with two intrachain disulfide bonds located at Cys1–Cys98 and Cys29–Cys138, and a calculated molecular mass of 19,271 Da. Because the host is a prokaryote, the product lacks the O-linked and N-linked glycan structures present in mammalian-cell-derived interferon alpha preparations. This absence of glycosylation alters hydrodynamic behavior, susceptibility to aggregation, and clearance, but does not remove the receptor-binding domain for IFNAR1 and IFNAR2. Potency is assigned by antiviral activity against the World Health Organization international standard for interferon alfa-2b and is expressed in international units per milligram of protein. Parenteral-grade release material is ordinarily controlled to not less than 1.0×10⁸ IU/mg protein, with the assigned value reported on a batch-specific certificate of analysis.

Pharmaceutical-grade status indicates manufacture under ICH Q7, EU GMP Annex 2, and applicable sections of 21 CFR 210/211, with viral safety assurance based on ICH Q5A, cell-substrate documentation under ICH Q5D, and specification design under ICH Q6B. Residual host-cell protein, host-cell DNA, endotoxin, and bioburden are not fixed identically for all presentations; the maximum tolerated values depend on whether the API is intended for injection, capsule, tablet, granule, or effervescent solid oral use. The title should be read as a formulation-capable API designation, not as a finished tablet. The active ingredient is supplied to a dosage-form manufacturer, which then introduces the protein into acid-base effervescent matrices, dry blends, granules, or sterile injectable formulations under conditions that must be qualified separately.

What Distinguishes Interferon Alfa-2b from Interferon Alfa-2a and Pegylated Interferon Alfa-2b?

At residue 23 of the mature polypeptide, interferon alfa-2b contains arginine, whereas interferon alfa-2a contains lysine. The remaining primary sequences are identical. Both alfa-2a and alfa-2b are produced in E. coli and are therefore non-glycosylated. Mammalian-cell-expressed interferon alfa subtypes, by contrast, carry glycan decoration that can reduce aggregation propensity, change net charge, and prolong circulating half-life. Pegylation of interferon alfa-2b attaches a monomethoxy polyethylene glycol moiety to the protein surface, increasing hydrodynamic radius and reducing renal clearance. Published pharmacokinetic data after subcutaneous administration of unpegylated interferon alfa-2b indicate an elimination half-life generally in the range of 2–8 h, while pegylated interferon alfa-2b exhibits a terminal half-life near 40 h. The distinction is therapeutically relevant because the unpegylated protein requires more frequent administration and may be more vulnerable to proteolytic loss if delivered by the oral route.

Release Specifications and Stability Boundaries Across Oral Solid and Parenteral Grades

Release criteria for parenteral-grade interferon alfa-2b differ from those applied to tablet, capsule, and granule grades. Injectable material is controlled for sterility by membrane filtration according to Ph. Eur. 2.6.1 or USP <71>, and for subvisible particulate matter by light obscuration using Ph. Eur. 2.9.19 or USP <788>. Compendial limits for large-volume parenterals are not necessarily identical to those for small-volume protein injections, but the standard acceptance thresholds of 6000 particles per container at ≥10 µm and 600 particles per container at ≥25 µm are frequently applied for reconstituted injectable solutions. Bacterial endotoxin is tested by limulus amebocyte lysate methods under Ph. Eur. 2.6.14 or USP <85>, with the limit calculated from the maximum intended injectable dose according to Ph. Eur. 5.1.10 or USP <85>. Solid oral grades are controlled by microbial enumeration using Ph. Eur. 5.1.4 or USP <61>/<62>, with typical acceptance criteria for non-sterile oral preparations at not more than 10² CFU/g total aerobic microbial count and not more than 10¹ CFU/g total yeast and mold count. Water content is not a universal parameter; for a protein-containing granule it may be specified below 5.0% loss on drying, while the acid-carbonate effervescent base is usually required to remain below 0.5% free moisture to avoid premature carbon dioxide generation during processing and storage.

When Effervescent Granulation Imposes Acid-Base and Moisture Constraints on Protein APIs

Effervescent tablet manufacture combines an acid, typically anhydrous citric acid or tartaric acid, with a carbonate source such as sodium bicarbonate or sodium carbonate. Upon contact with water, the reaction releases carbon dioxide and produces a buffered solution; the initial local pH can fall below 4.0 before neutralization is complete. Interferon alfa-2b is most stable in aqueous formulations between pH 6.8 and 7.4, and acid exposure can induce unfolding, deamidation, and covalent aggregation. The stoichiometry of the acid-base couple also matters: one mole of anhydrous citric acid can react with 3 moles of sodium bicarbonate to generate 3 moles of carbon dioxide, so even small amounts of free moisture can initiate effervescence and increase tablet porosity during storage. For this reason the protein is preferably isolated from the effervescent couple in a separate granule, or dry-blended under strictly controlled humidity.

Granulators handling the protein-containing fraction should operate with inlet air dew point not exceeding 5°C and relative humidity below 20%. Fluid-bed top-spray granulation with an aqueous binder exposes the protein to water for the duration of drying; if inlet temperature exceeds 40°C, thermal unfolding may accelerate. Dry granulation by slugging or roller compaction reduces moisture and thermal load but introduces shear stress at the compaction zone. Rotary tablet presses used for effervescent formulations should be equipped with external lubrication to avoid overmixing of magnesium stearate, and compression force is typically maintained between 10 kN and 20 kN to produce tablet hardness below 60 N as measured by USP <1217>. These conditions balance sufficient mechanical strength against rapid disintegration. High compaction pressure and long dwell time can collapse the porous structure required for effervescent tablets and can increase protein particle surface contact, favoring aggregation during storage.

Lyophilization and Spray Drying Alter the Solid-State Conformation of Interferon Alfa-2b

Parenteral-grade interferon alfa-2b is often supplied as a lyophilized cake from a buffered solution containing sodium phosphate, glycine, or trehalose as a stabilizer. Lyophilization embeds the protein in an amorphous matrix; residual moisture after lyophilization is conventionally specified at or below 2.0%. Spray drying for oral solid grades creates particles with high surface area and may introduce shear and air-water interface stress. If inlet temperature is above 60°C, surface denaturation and aggregate formation can occur even when the outlet temperature remains below the measured unfolding temperature of the protein. Trehalose or sucrose is preferred as a lyoprotectant for both lyophilized injection-grade and spray-dried oral-grade material. Reducing sugars such as glucose or maltose must be excluded because their aldehyde groups can undergo Maillard reactions with lysine residues of the protein, reducing potency and generating covalent adducts.

Although the product title includes oral and injectable routes, oral administration of unmodified interferon alfa-2b is constrained by proteolytic degradation in the gastrointestinal tract and by negligible passive permeation across the intestinal epithelium. An effervescent tablet can deliver the protein into a buffered solution and may provide brief residence in the oral cavity, but it does not eliminate enzymatic hydrolysis in the stomach and small intestine. Published data for this specific oral effervescent configuration is limited; injectable presentations remain the route for which the pharmacokinetics and pharmacodynamics of interferon alfa-2b are most extensively characterized. Differences from other interferon products therefore arise at three levels: primary sequence variation at residue 23 compared with alfa-2a, absence of glycan decoration compared with mammalian cell-expressed interferons, and attachment of polyethylene glycol in pegylated forms. Each difference influences immunogenicity, receptor occupancy, elimination, and the selection of formulation stabilizers.

Incompatibilities relevant to the API include strong oxidizing agents, alkaline conditions above pH 9.0, and prolonged exposure to silicone oil from prefilled syringe components. For solid oral manufacture, the API should not be dry-mixed with acidic components in the presence of free water, and product-contact surfaces should be passivated stainless steel to reduce metal-ion-catalyzed oxidation of methionine residues. Batch-to-batch variance in host-cell protein levels and aggregate content is controlled by process validation under ICH Q5A and ICH Q5E, but exact limits remain manufacturer-specific because the route of administration and maximum daily dose determine the permitted residual impurity load.